PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

Core Insights - PolyPid Ltd. has appointed Dr. Nurit Tweezer-Zaks as Chief Medical Officer, effective August 18, 2025, transitioning from her role on the Board of Directors [1][2][3] - The appointment comes after positive results from the Phase 3 SHIELD II trial, as the company prepares for a New Drug Application (NDA) submission for its lead product candidate, D-PLEX₁₀₀ [2][4] - Dr. Tweezer-Zaks brings extensive experience in medical and executive roles, including her previous position as CEO of MediCane Health Inc. and senior roles at aMOON Venture Capital Fund and Sanofi [2][3] Company Overview - PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through its proprietary PLEX technology, which allows for controlled, prolonged-release therapeutics [4] - The company is preparing for an NDA submission for D-PLEX₁₀₀, aimed at preventing abdominal colorectal surgical site infections, expected in early 2026 [4] - PolyPid has a pipeline that includes innovative programs in oncology, obesity, and diabetes [4]